1. Generics Bulletin
  2. >>Business

Lannett New York Listing Under Threat As FDA Says No On Advair

Flurry Of Announcements Also Sees Lannett Agree Sale Of Carmel Site

 
• By Dean Rudge

A strained balance sheet and share price has led the New York Stock Exchange to write to Lannett about its future listing, adding to its woes as the FDA confirmed it was not currently in a position to approve its partnered generic Advair Diskus asset.

Clock disintegrates, time running out concept
Lannett has 45 days to submit a business plan to the NYSE • Source: Piotr Adamowicz / Alamy Stock Photo

An expected complete response letter denying approval for Lannett’s proposed generic version of Advair Diskus (fluticasone/salmeterol) has been returned to the firm, at the same time as the US-based manufacturer disclosed that its lower-than-$1 share price was threatening the firm’s listing on the New York Stock Exchange.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Generics Bulletin

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.